Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, prospective, age descending, randomized, two arm, single blind, parallel, active controlled, multicentre, non-inferiority, phase II/III clinical study to evaluate the immunogenicity and safety of Tetanus vaccine (adsorbed) of M/s BioVaccines (India) Pvt. Ltd. compared to Tetanus vaccine (adsorbed) of M/s Serum Institute of India Limited in healthy subjects aged 10-60 years of age - TT Phase III trial

Trial Profile

An open label, prospective, age descending, randomized, two arm, single blind, parallel, active controlled, multicentre, non-inferiority, phase II/III clinical study to evaluate the immunogenicity and safety of Tetanus vaccine (adsorbed) of M/s BioVaccines (India) Pvt. Ltd. compared to Tetanus vaccine (adsorbed) of M/s Serum Institute of India Limited in healthy subjects aged 10-60 years of age - TT Phase III trial

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs Tetanus vaccine (Primary)
  • Indications Tetanus
  • Focus Registrational; Therapeutic Use
  • Sponsors Bio Vaccines
  • Most Recent Events

    • 13 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top